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Gene polymorphismChronic glomerulonephritis (CGN) is one of the most severe kidney diseases. Genes of vascular reactivity are
thought to play an important role in development and progression of CGN. In this study, we analyzed association
of genes of vascular homeostasis with hypertension and renal survival of CGN patients. The study sample includ-
ed 238 patientswith CGN and304 healthy subjects of population control. Ten polymorphisms of ten genes of vas-
cular homeostasis were genotyped through polymerase chain reaction (PCR), restriction fragment length
polymorphism (RFLP) analysis and TaqManassays. Association of the genotypeswith renal survivalwas analyzed
by the Kaplan–Meier estimator. Genotypes 311SC and 311SS of the PON2 gene, (−1166)AC and (−1166)CC of
the AGTR1 gene, (+46)AA of the ADRB2 gene, and 198KK and 198KN of the EDN1 gene were associatedwith de-
creased rate of renal survival of thepatients. Polymorphisms S311C PON2, (−1166)A/CAGTR1, (+46)G/AADRB2,
and K198N EDN1were associated with the accelerated decline in kidney function in the CGN patients.
© 2014 Published by Elsevier B.V.1. Introduction
Chronic glomerulonephritis (CGN) is a genetically determined
immune-mediated glomerular disease, which often associated with hy-
pertension, and may result in renal failure and respective increased
mortality (Nickolas et al., 2004). Genes of vascular homeostasis play
an important role in development and progression of CGN. They regu-
late renal hemodynamics, mesangial cell proliferation, synthesis and
degradation of extracellular matrix, and the rate of development of
glomerulosclerosis (Egido, 1996; Jensen and Pedersen, 1997).
CGN often results in development of arterial hypertension (AH).
There is a close relationship between hypertension and renal function
(Best and Holmes, 2003). Impaired excretion of sodium and water by
kidneys is considered as one of the main mechanisms of essentialarterial hypertension; BP, blood
d pressure; GFR, glomerular ﬁl-
eotide polymorphism; ACE, an-
e 3; PON2, paraoxonase-2; AGT,
; EDN1, endothelin 1; CYP3A5,
NB3, guanine nucleotide bind-
, adducin 1 (alpha); ADRB2,
E, Hardy–Weinberg equilibri-
nferroni correction.
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v).hypertension. In turn, essential hypertension contributes to kidney
impairment through vasoconstriction, structural changes in renal arteri-
oles, and parenchymal ischemia (Best and Holmes, 2003). Pathogenesis
of arterial hypertension in renal disease is complex. One of themain fac-
tors is the activation of pressor hormone systems (sympathoadrenal
system, renin–angiotensin–aldosterone system, endothelial constrictor
hormones, endothelin). Therefore, genetic markers of these hormones
have attracted an increased attention in recent years as possible risk fac-
tors for glomerulopathy (Buraczynska et al., 2006).
In this study, we examined polymorphisms of the genes of vascular
homeostasis for their possible association with development of hyper-
tension and renal survival in Russian patients suffering from CGN. The
polymorphismswere selected on the basis of their possible contribution
to pathogenesis of CGN and effect on expression of the genes. In partic-
ular, allele D at locus I/D of theACE gene confers higher expression to the
enzyme than allele I (Ueda et al., 1996). Allele (−6)A of the AGT gene is
associated with higher expression of angiotensinogen (Brand et al.,
2000). The (−1166)A/C polymorphism of the AGTR1 gene is known to
alter the structure of a cis-element within the gene that increases gene
expression (Wang et al., 2006). Homozygotes 4a4a of the NOS3 gene
have lower activity of the enzyme as compared to the 4b4b homozy-
gotes (Dosenko et al., 2006). Allele (+6986)A of the CYP3A5 gene is as-
sociated with increased expression of the respective enzyme (Givens
et al., 2003). Importantly, the above polymorphisms have been associat-
ed with the risk of hypertension in various diseases (Calle et al., 2006;
Misono et al., 2009; Tiret et al., 1999).
Table 1
Characteristics of the subjects from the case and control groups.
Characteristics Cases Controls
Total 238 304
Males 127 (53.4%)⁎ 164 (53.9%)
Females 111 (46.6%)⁎ 140 (46.1%)
Age, years 39.58 ± 14.58⁎ 42.20 ± 6.28
Weight, kg 63.4 ± 2.1⁎ 67.4 ± 1.7
Height, cm 165.4 ± 3.4⁎ 168.6 ± 2.7
SBP, mm Hg 148.4 ± 26.5⁎⁎ 128.1 ± 4.4
DBP, mm Hg 92.7 ± 14.0⁎⁎ 82.2 ± 2.0
Creatinine, μmol/l 337.2 ± 44.1⁎⁎ 130.4 ± 7.8
GFR, ml/min 28.2 ± 1.8 81.6 ± 3.4
⁎ p N 0.05.
⁎⁎ p b 0.001.
Table 2
Summary information about the studied polymorphisms.
Polymorphism Studied
groups
Minor allele MAF (%) HWE
χ2 p
I/D ACE Case I ACE 45.09 0.87 N0.05
I/D ACE Control I ACE 48.18 0.19 N0.05
4a/4b NOS3 Case 4a NOS3 21.37 0.26 N0.05
4a/4b NOS3 Control 4a NOS3 19.50 0.90 N0.05
S311C PON2 Case 311C PON2 24.58 0.17 N0.05
S311C PON2 Control 311C PON2 28.12 0.75 N0.05
(−6)A/G AGT Case (−6)G AGT 48.11 0.06 N0.05
(−6)A/G AGT Control (−6)G AGT 47.69 1.38 N0.05
(−1166)A/C AGTR1 Case (−1166)C AGTR1 26.18 1.01 N0.05
(−1166)A/C AGTR1 Control (−1166)C AGTR1 25.99 0.19 N0.05
G/A GNB3 Case A GNB3 34.18 0.24 N0.05
G/A GNB3 Control A GNB3 31.68 0.41 N0.05
G460W ADD1 Case 460W ADD1 16.31 13.55 b0.001
G460W ADD1 Control 460W ADD1 15.13 1.84 N0.05
(+46)G/A ADRB2 Case (+46)A ADRB2 36.86 2.01 N0.05
(+46)G/A ADRB2 Control (+46)A ADRB2 39.93 1.26 N0.05
K198N EDN1 Case 198N EDN1 17.02 0.30 N0.05
K198N EDN1 Control 198N EDN1 18.54 0.38 N0.05
(+6986)G/A CYP3A5 Case (+6986)A CYP3A5 7.48 1.53 N0.05
(+6986)G/A CYP3A5 Control (+6986)A CYP3A5 5.92 0.93 N0.05
Notes: MAF, minor allele frequency; HWE, Hardy–Weinberg equilibrium. p values were
calculated using the χ2 test.
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2.1. Subjects
The study protocol was approved by the Ethics Committee of
Belgorod State National Research University. All subjects signed an
informed consent before entering the study. In total 542 subjects, in-
cluding 238 patients with CGN and 304 individuals of population con-
trol, were recruited for this study. All study subjects were unrelated
Russians from Central Chernozem Region of Russia (Belgorod). Patients
were enrolled in the case group only after the clinically conﬁrmed diag-
nosis of CGN. Clinical and laboratory examination of patients was con-
ducted at the Nephrology Clinic of Belgorod Regional Clinical Hospital.
Blood samples were taken during the period of the patient's hospi-
talization. The patients were examined monthly by a nephrologist for
the period of 6 months to 1 year. Blood pressure (BP) level was mea-
sured daily in the morning, in the upper-sitting position of the patient.
At least 3 measurements were made and the average systolic blood
pressure (SBP) and diastolic blood pressure (DBP) were calculated.
SBP≥ 140mmHg and/or DBP≥ 90mmHgwere considered as an indi-
cation of AH. BP ≥ 160/100 mmHg in patients taking antihypertensive
drugs was considered as an indicator of severe course of AH. The exclu-
sion criteria for the CGNpatientswere the history of diabetesmellitus or
hypertension.
Renal survival in patients with CGN was assessed in a group of 138
individuals with non-terminal renal failure. Of these, 104 patients had
normal renal function (creatinine level b140 μmol/l) and 34 patients
had chronic renal failure (creatinine level was 140 μmol/l during
6 months of observation). The progress of chronic renal failure was an-
alyzed from the onset of the disease. The endpoint of the observation
was doubling of baseline creatinine. Renal function was assessed
through glomerular ﬁltration rate (GFR) which was estimated by
Cockroft–Gault's formula (Cockcroft and Gault, 1976).
2.2. DNA isolation
Genomic DNA was isolated from 10 ml of whole blood using a
method proposed by Miller et al. (1988).
2.3. Genotyping
The ten DNA polymorphisms were genotyped through the analysis
of ampliﬁed fragment length polymorphism (I/D polymorphism of the
ACE gene, VNTR polymorphism of the NOS3 gene), the analysis of re-
striction fragment length polymorphisms (S311C of the PON2 gene
(rs7493), −6A/G the AGT gene (rs5051), −1166A/C of the AGTR1
gene (rs5186)) and Tag-Man allele discrimination analysis (K198N of
the EDN1 gene (rs5370), +6986G/A of the CYP3A5 gene (rs776746),
G/A (rs2301339) of the GNB3 gene (rs2301339), G460W of the ADD1
gene, +46G/A of the ADRB2 gene (rs1042713)). The structure of the
primers and PCR conditions for genotyping the DNA polymorphisms
are described in detail elsewhere (Agerholm-Larsen et al., 2000; Asai
et al., 2001; Jalilian et al., 2008; Lanfear et al., 2005; Picard et al., 2007;
Prasad et al., 2006; Yazdanpanah et al., 2007).
2.4. Statistical analysis
The allele frequencies were checked for departures from the Hardy–
Weinberg equilibrium (HWE) using the chi-square test. Association of
the DNA markers with CGN in hypertensive patients was assessed
through the chi-square test with Yates' correction. Odds ratios (ORs)
and 95% conﬁdence intervals (CIs) were used to estimate the associa-
tion between the polymorphisms and the risk of CGN in the hyperten-
sive patients. The calculations were adjusted for multiple testing by
Bonferroni correction (pc).The patients were divided into three groups according to their
BP: below 140/90 mm Hg (the ﬁrst group, 84 patients, 36.2%), from
140/90 to 159/100 mm Hg (the second group, 96 patients, 41.4%), and
above 160/110 mm Hg (the third group, 52 patients, 22.4%).
Association of renal survival with the genotypes was analyzed using
the Kaplan–Meier test. A software package STATISTICA for Windows v.
6.0 (StatSoft, Inc.) was used for the analyses.
3. Results
The average age of the CGN patients and the population control
subjects was similar (39.58 ± 14.58 years and 42.20 ± 6.28 years,
respectively, p N 0.05). The main characteristics of the study
subjects are shown in Table 1. Notably, patients with CGN had
higher levels of both systolic (148.4 ± 26.5 mm Hg) and diastolic
(92.7 ± 14.0 mm Hg) blood pressures as compared to the control
group (p b 0.001). As shown in Table 1, creatinine level in patients
with CGN was 337.2 ± 44.1 μmol/l, signiﬁcantly higher than that in
the control group (p b 0.001). Glomerular ﬁltration rate in CGN patients
was 28.2 ± 1.8 ml/min, which was signiﬁcantly lower than that in the
control group (p b 0.001).
All studied DNA polymorphisms (except G460W of the ADD1
gene, p b 0.05) showed no deviation from the HWE (Table 2).
No statistically signiﬁcant differences in allele and genotype fre-
quencies were found between the CGN patients and the controls
(p N 0.05).
Table 3
Comparative analysis of genotype frequencies of polymorphicmarkers of genes of vascular homeostasis in patientswith chronic glomerulonephritis dependingon the level of blood pressure.
Locus Genotype Controls
(n = 304)















1–2 1–3 1–4 2–3 2–4 3–4
I/D ACE II 72 (23.84) 14 (17.07) 18 (18.95) 10 (19.61) 0.25 0.39 0.63 0.90 0.89 1.00
ID 147 (48.68) 45 (54.88) 46 (48.42) 29 (56.86) 0.38 1.00 0.35 0.48 0.97 0.43
DD 83 (27.48) 23 (28.05) 31 (32.63) 12 (23.53) 1.00 0.40 0.68 0.62 0.71 0.34
4a/4b NOS3 4a4a 14 (4.67) 6 (7.32) 6 (6.38) 0 (0.00) 0.50 0.70 0.23 1.00 0.12 0.16
4a4b 89 (29.67) 21 (25.61) 35 (37.23) 19 (36.54) 0.56 0.21 0.41 0.14 0.25 1.00
4b4b 197 (65.66) 55 (67.07) 53 (56.38) 33 (63.46) 0.92 0.13 0.88 0.20 0.81 0.51
S311C PON2 311CC 21 (6.91) 3 (3.62) 8 (8.42) 1 (1.92) 0.40 0.79 0.29 0.31 0.97 0.23
311SC 129 (42.43) 36 (43.37) 30 (31.58) 22 (42.31) 0.98 0.08 1.00 0.14 1.00 0.26
311SS 154 (50.66) 44 (53.01) 57 (60.00) 29 (55.77) 0.80 0.14 0.60 0.43 0.89 0.75
(−6)A/G AGT (−6)AA 92 (30.36) 29 (34.94) 19 (19.79) 14 (26.92) 0.51 0.06 0.74 0.04 0.43 0.43
(−6)AG 136 (44.89) 34 (40.96) 58 (60.42) 27 (51.92) 0.61 0.01 0.43 0.02 0.44 0.41
(−6)GG 75 (24.75) 20 (24.10) 19 (19.79) 11 (21.16) 0.94 0.39 0.70 0.61 0.85 1.00
(−1166)A/C AGTR1 (−1166)AA 168 (55.26) 38 (46.34) 54 (57.45) 27 (52.94) 0.19 0.80 0.88 0.19 0.57 0.73
(−1166)AC 114 (37.50) 41 (50.00) 33 (35.11) 21 (41.18) 0.05 0.77 0.73 0.07 0.42 0.59
(−1166)CC 22 (7.24) 3 (3.66) 7 (7.45) 3 (5.88) 0.36 1.00 0.96 0.45 0.87 0.99
G/A GNB3 (rs2301339) GG 139 (45.88) 34 (40.96) 40 (41.67) 23 (44.23) 0.50 0.55 0.95 1.00 0.85 0.90
GA 136 (44.88) 38 (45.78) 48 (50.00) 22 (42.31) 0.98 0.44 0.85 0.68 0.83 0.47
AA 28 (9.24) 11 (13.26) 8 (8.33) 7 (13.46) 0.39 0.95 0.49 0.41 0.55 0.48
G460W 460WW 10 (3.29) 6 (7.23) 6 (6.26) 2 (3.92) 0.20 0.32 1.00 1.00 0.68 0.83
ADD1 460GW 72 (23.68) 12 (14.46) 35 (26.04) 12 (23.53) 0.10 0.74 1.00 0.08 0.27 0.89
460GG 222(73.0 3) 65 (78.31) 65 (67.71) 37 (72.55) 0.41 0.38 1.00 0.16 0.58 0.68
(+46) (+46)GG 114 (37.62) 30(36.14) 39 (41.05) 18 (34.61) 0.91 0.63 0.80 0.61 1.00 0.56
G/A (+46)GA 136 (44.88) 43(51.81) 45(47.37) 28 (53.85) 0.32 0.80 0.30 0.61 0.96 0.52
ADRB2 (+46)AA 53 (17.50) 10(12.05) 11(11.58) 6 (11.54) 0.31 0.23 0.39 1.00 1.00 1.00
K198N 198KK 202 (66.89) 59 (71.08) 61 (64.89) 38 (73.08) 0.55 0.82 0.47 0.47 0.96 0.41
EDN1 198KN 88 (29.14) 19 (22.89) 30 (31.91) 14 (26.92) 0.32 0.71 0.87 0.24 0.75 0.66
198 NN 12 (3.97) 5 (6.03) 3 (3.20) 0 (0.00) 0.61 0.97 0.30 0.59 0.18 0.49
(+6986) (+6986) GG 270 (88.81) 72 (87.80) 79 (84.04) 42 (80.77) 0.95 0.29 0.16 0.62 0.39 0.79
G/A (+6986) GA 32 (10.53) 10 (12.20) 15 (15.96) 10 (19.23) 0.82 0.21 0.12 0.62 0.39 0.79
CYP3A5 (+6986) AA 2(0.66) 0 (0.00) 0 (0.00) 0 (0.00) 1.00 1.00 1.00 1.00 1.00 1.00
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the BP level in the CGN patients are shown in Table 3. No signiﬁcant as-
sociationwas detected between the polymorphisms and blood pressure
level. Then a subgroup of 138 CGN patients (68 men and 70 women)
was used to perform the survival analysis. Thirty four patients had a
doubling of baseline creatinine. The average age of these patients was
41.53 ± 1.31 years, duration of the disease was 9.87 ± 0.85 years.
The accelerated decline in renal function (early development of
chronic kidney failure) was signiﬁcantly associated with the genotypes
of the four polymorphisms (Figs. 1–4). In particular, genotypes 311SC
and 311SS of the PON2 gene (Fig. 1), (−1166)AC and (−1166)CC ofFig. 1.Renal survival of CGNpatientswith different genotypes of the S311C polymorphism
of the PON2 gene. Genotypes 311SS and 311SC PON2 aremarked by dashed line, genotype
311CC PON2 ismarked by full line. All differences are signiﬁcant (p= 0.05). Renal survival
is expressed in months.the AGTR1 gene (Fig. 2), (+46)AA of the ADRB2 gene (Fig. 3), and
198KK and 198KN of the EDN1 gene (Fig. 4) were found to be associated
with renal failure survival in patients suffering from CGN.4. Discussion
Genes of vascular homeostasis have traditionally been a subject of
interest. Some mutations in these genes alter their expression level,
which, in turn, may affect the development of chronic inﬂammatory
process. However, the data about the role of individual polymorphismsFig. 2. Renal survival of CGN patients with different genotypes of the (−1166)A/C poly-
morphism of the AGTR1 gene. Genotypes (−1166)AC and (−1166)CC AGTR1 are marked
by dashed line, genotype (−1166)AA AGTR1 is marked by full line. All differences are sig-
niﬁcant (p = 0.008). Renal survival is expressed in months.
Fig. 3. Renal survival of CGN patients with different genotypes of the (+46)G/A polymor-
phism of the ADRB2 gene. Genotype (+46)AA ADRB2 is marked by full line, genotypes
(+46)AA and (+46) GG ADRB2 are marked by dashed line. All differences are signiﬁcant
(p = 0.05). Renal survival is expressed in months.
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ease are often inconsistent (Buraczynska et al., 2006).
An important role of hemodynamic disorders (including those asso-
ciated with arterial hypertension) in the progression of nephropathy
has been supported by other studies (Brown and Whitworth, 1992;
Losito et al., 2003). The relationship between pathological processes in
kidneys and the development of arterial hypertension is ambilateral.
On the one hand, renal pathology itself may cause hypertension, on
the other hand, kidney function depends on the blood pressure level.
In CGN, glomeruli, which survived after the initial injury, undergo adap-
tive changes in order to compensate the loss of functional renal tissue.
Increased glomerular function is associated with signiﬁcant changes in
renal hemodynamics, such as increased perfusion of the remaining
nephrons, the development of intraglomerular hypertension and renal
hyperﬁltration (Best and Holmes, 2003).
Herewe determined genetic factors, whichmay reduce renal surviv-
al. Two genotypes of the EDN1 gene K198N polymorphism, 198KK and
198KN, were associated with impaired renal function. Similar results
were obtained by Fei-Fei et al. (2008) who reported a decline in renal
function and the lower survival rate in carriers of the 198KK genotype.
Like angiotensin-II, endothelin-1 is a growth factor contributing to the
increased production of extracellular matrix by ﬁbroblasts, mesangial
and epithelial cells and, therefore, may take part in the development
of glomerulosclerosis.
The observed associations of the AGTR1 variants with decreased
renal survival in the CGN patients may be related to the vasoconstrictor
effect of the respective protein (Wang et al., 2006), which is apparentlyFig. 4. Renal survival of CGN patients with different genotypes of the K198N polymor-
phism of the EDN1 gene. Genotypes 198KK and 198KN EDN1 aremarked by full line, geno-
type 198NN EDN1 is marked by dashed line. All differences are signiﬁcant (p = 0.05).
Renal survival is expressed in months.more pronounced in the patients with high-yielding allele (−1166)C.
Previously Buraczynska et al. (2006) found that the average time of
the end stage renal diseasewas signiﬁcantly shorter in patients with ge-
notypes (−1166)AC and (−1166)CC than in those with genotype
(−1166)AA.
A number of studies showed association of the (+46)G/A polymor-
phism in the ADRB2 gene with hypertension (Masuo et al., 2005;
Misono et al., 2009). We found that genotype AA of this SNP
confers lower renal survival to the CGN patients. Elevated expression
of β2-adrenoceptor in the juxtaglomerular apparatus of kidneys results
in the increased release of renin and, consequently, activation of the
renin–angiotensin–aldosterone system. The main player in this system,
angiotensin II, causes both systemic and kidney-speciﬁc local spasm of
arterioles and an associated increase in both total peripheral vascular
resistance and renal vascular resistance, elevates sodium reabsorption
by acting directly on renal tubules, and stimulates renal hypertrophy
and proteinuria.
5. Conclusions
The results of the present study suggest that genotypes 311SC and
311SS of the PON2 gene, (−1166)AC and (−1166)CC of the AGTR1
gene, (+46)AA of the ADRB2 gene, and 198KK and 198KN of the
EDN1may contribute to renal function decline.
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